SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for Scilex Holding (SCLX) — Jun 9, 2026

Scilex Holding Co
Date: June 9, 2026 · CIK: 0001820190 · Accession: 0000000000-26-005809

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-296430

Date
June 9, 2026
Author
Division of
Form
UPLOAD
Company
Scilex Holding Co

Letter

Re: Scilex Holding Company Registration Statement on Form S-3 Filed June 2, 2026 File No. 333-296430 Dear Henry Ji: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions.

June 9, 2026

Henry Ji Chief Executive Officer & President Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Elizabeth A. Razzano, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 June 9, 2026

Henry Ji
Chief Executive Officer & President
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303

 Re: Scilex Holding Company
 Registration Statement on Form S-3
 Filed June 2, 2026
 File No. 333-296430
Dear Henry Ji:
 This is to advise you that we have not reviewed and will not review your
registration
statement.
 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you that
the company and its management are responsible for the accuracy and adequacy of
their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
 Please contact Alan Campbell at 202-551-4224 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Elizabeth A. Razzano, Esq.
</TEXT>
</DOCUMENT>